ArticleThe Veterinary record
Anti-desmoglein-2 autoantibodies do not discriminate between UK boxer dogs with and without arrhythmogenic right ventricular cardiomyopathy.
Article in The Veterinary record. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundEvidence regarding the diagnostic utility of serum anti-desmoglein-2 (DSG2) autoantibodies for arrhythmogenic right ventricular cardiomyopathy (ARVC) in boxer dogs is conflicting.
methodsProspective standardised evaluation of apparently healthy boxer dogs for ARVC was performed at three referral centres, including blood pressure measurement, electrocardiography, echocardiography, haematology, biochemistry (including cardiac troponin I) and 24-hour Holter monitoring. Additional dogs with a diagnosis of ARVC were retrospectively recruited. ARVC disease status was defined using cut-offs of 20 or less (unaffected) and more than 300 (affected) ventricular premature complexes of right ventricular origin in 24 hours. The residual serum samples were stored at ‒80°C for analysis for anti-DSG2 autoantibodies using ELISA techniques.
resultsForty boxer dogs were enrolled (11 healthy controls, 10 with preclinical ARVC and 19 with clinical ARVC). Serum anti-DSG2 autoantibodies were detected in all dogs, bar one healthy dog. DSG2 differed significantly between groups (p = 0.031) and was significantly lower in dogs with preclinical versus clinical ARVC (p = 0.025). LIMITATIONS: Some data were collected retrospectively, and some dogs were receiving antiarrhythmic therapy.
conclusionSerum DSG2 autoantibodies can be present in boxer dogs with preclinical and clinical ARVC and apparently healthy controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.